Multiple primary cancers in patients with osteosarcoma: Influence of anticancer drugs and genetic factors

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 3, 2004, Pages 220-224

  Yonemoto, Tsukasa ^a   Tatezaki, Shin Ichiro ^a   Ishii, Takeshi ^a   Hagiwara, Yoko ^a   Inoue, Masatoshi ^b  

^a CHIBA CANCER CENTER   (Japan)

^b National Chiba Higashi Hospital   (Japan)

Author keywords

Chemotherapy; Germ line p53 gene mutation; Multiple primary cancers; Osteosarcoma

Indexed keywords

ACLARUBICIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PROTEIN P53; VINBLASTINE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; ARTICLE; BREAST CARCINOMA; CANCER CENTER; CHILDHOOD CANCER; CYSTOSARCOMA PHYLLOIDES; FAMILIAL CANCER; FEMALE; FOLLOW UP; GENE MUTATION; GERM LINE; HEREDITY; HUMAN; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; ONSET AGE; OSTEOSARCOMA; OVARY CARCINOMA; PEDIGREE; POLYMERASE CHAIN REACTION; SECOND CANCER; SINGLE STRAND CONFORMATION POLYMORPHISM; TERATOMA; UTERUS SARCOMA; YOLK SAC TUMOR;

ADOLESCENT; ADULT; AGE OF ONSET; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; GENES, P53; GERM-LINE MUTATION; HUMANS; INFANT; MALE; NEOPLASMS, SECOND PRIMARY; OSTEOSARCOMA; TIME FACTORS;

EID: 2942627104     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.COC.0000054534.43117.76     Document Type: Article

References (30)

1. Whelan JS. Osteosarcoma. Eur J Cancer 1997;33:1611-9.
2. McIntyre JF, Smith-Sorensen B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 1994;12:925-30.
3. Meadows AT, Strong LC, Li FP, et al. Bone sarcoma as a second malignant neoplasm in children. Influence of radiation and genetic predisposition. Cancer 1980;46:2603-6.
4. Tucker MA, D'Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987;317:588-93.
5. Vu BL, deVathaire FR, Shamsaldin A, et al. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int J Cancer 1998;77:370-7.
6. Enneking WF, Spanier SS, Goodman MA. System for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980;153:106-20.
7. Toguchida J, Yamaguchi T, Ritchie B, et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 1992;52:6194-9.
8. Orita M, Suzuki Y, Sekiya T, et al. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989;5:874-9.
9. Radig K, Schneider-Stock R, Haeckel C, et al. p53 gene mutation in osteosarcomas of low-grade malignancy. Hum Pathol 1998;29:1310-6.
10. Yandell D, Dryja T. Detection of DNA sequence polymorphisms by enzymatic amplification and direct genomic sequencing. Am J Hum Genet 1989;45:547-55.
11. Varley JM, Evans DGR, Birch JM. Li-Fraumeni syndrome. A molecular and clinical review. Br J Cancer 1997;76:1-14.
12. Ferrari C, Bohling T, Benassi MS, et al. Secondary tumors in bone sarcomas after treatment with chemotherapy. Cancer Detect Prev 1999;23:368-74.
13. Pratt CB, Meyer WH, Luo X, et al. Second malignant neoplasms occurring in survivors of osteosarcoma. Cancer 1997;80:960-5.
14. Longhi A, Gamberi G, Bacci G. Brain tumors as second malignant neoplasms in patients with osteosarcoma treated with adjuvant and neoadjuvant chemotherapy: report of 2 cases. J Chemother 2000;12:261-2.
15. Verneris M, McDougall IR, Becton D, et al. Thyroid carcinoma after successful treatment of osteosarcoma: a report of three patients. J Pediatr Hematol Oncol 2001;23:312-5.
16. Bechler JR, Robertson WW, Meadows AT, et al. Osteosarcoma as a second malignant neoplasm in children. J Bone Joint Surg [Am] 1992;74:1079-83.
17. Bielack SS, Kempf-Bielack B, Heise U, et al. Combined modality treatment for osteosarcoma occurring as a second malignant disease. J Clin Oncol 1999;17:1164-74.
18. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 1986;53:661-71.
19. Pratt CB, Meyer WH, Rao BN, et al. Comparison of primary osteosarcoma of flat bones with secondary osteosarcoma of any site. Cancer 1997;80:1171-7.
20. Yonemoto T, Tatezaki S, Ishii T, et al. Two cases of osteosarcoma occurring as second malignancy of childhood cancer. Anticancer Res 1999;19:5563-6.
21. Chauveinc L, Mosseri V, Quintana E, et al. Osteosarcoma following retinoblastoma: age at onset and latency period. Ophthalmic Genet 2001;22:77-88.
22. Iwata A, Hirota T, Konno K, et al. Osteosarcoma as a second malignancy after treatment for neuroblastoma. Pediatr Hematol Oncol 2001;18:465-9.
23. Meadows AT, Baum E, Fossati-Bellani F, et al. Second malignant neoplasms in children. An update from the late effects study group. J Clin Oncol 1985;3:532-8.
24. Heyn R, Haeberlen V, Newton WA, et al. Second malignant neoplasms in children treated for rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee. J Clin Oncol 1993;11:262-70.
25. Kagan VE, Yalowich JC, Borisenko GG, et al. Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia, Free radical/antioxidant approach. Mol Pharmacol 1999;56:494-506.
26. Burke E, Li FP, Janov AJ, et al. Cancer in relatives of survivors of childhood sarcoma. Cancer 1991;67:1467-9.
27. Carnevale A, Lieberman E, Cardenas R. Li-Fraumeni syndrome in pediatric patients with soft tissue sarcoma or osteosarcoma. Arch Med Res 1997;28:383-6.
28. Li FP, Fraumeni JF Jr. Rhabdomyosarcoma in children. Epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969;43:1365-73.
29. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
30. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999;286:2528-31.